ADCT-601

DRUG2 trials

Sponsors

ADC Therapeutics S.A.

Conditions

Advanced Solid Tumors

Phase 1

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

TerminatedNCT03700294

ADC Therapeutics S.A.Advanced Solid Tumors

Start: 2018-12-21End: 2019-12-11Updated: 2020-05-01

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

TerminatedNCT05389462

ADC Therapeutics S.A.Advanced Solid Tumors

Start: 2022-07-13End: 2025-04-17Updated: 2025-05-22

Related Papers

Abstract CT059: Phase 1b trial Mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas

Cancer Research2024-04-055 citations